Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
Johnson & Johnson
Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...
Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies
US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...
Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...
Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China
Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...